Perspective Therapeutics (NYSE:CATX) Rating Reiterated by Oppenheimer

Perspective Therapeutics (NYSE:CATXGet Free Report)‘s stock had its “outperform” rating restated by Oppenheimer in a report released on Tuesday, Benzinga reports.

Several other analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a report on Tuesday. B. Riley raised their price objective on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Perspective Therapeutics in a report on Friday. Finally, Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.00.

Read Our Latest Stock Analysis on CATX

Perspective Therapeutics Stock Performance

Shares of CATX traded up $0.78 during trading hours on Tuesday, reaching $11.12. 286,013 shares of the company traded hands, compared to its average volume of 477,686. Perspective Therapeutics has a 1-year low of $2.05 and a 1-year high of $19.05. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSE:CATXGet Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.33 million during the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. On average, equities research analysts forecast that Perspective Therapeutics will post -0.11 EPS for the current fiscal year.

Insider Activity

In other Perspective Therapeutics news, Director Robert F. Williamson III acquired 3,003 shares of Perspective Therapeutics stock in a transaction on Wednesday, May 29th. The shares were purchased at an average cost of $13.30 per share, with a total value of $39,939.90. Following the completion of the purchase, the director now owns 36,879 shares in the company, valued at $490,490.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Jonathan Robert Hunt bought 2,500 shares of the business’s stock in a transaction on Friday, May 31st. The shares were bought at an average cost of $14.00 per share, for a total transaction of $35,000.00. Following the completion of the acquisition, the chief financial officer now owns 34,171 shares in the company, valued at approximately $478,394. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert F. Williamson III bought 3,003 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was purchased at an average price of $13.30 per share, for a total transaction of $39,939.90. Following the completion of the acquisition, the director now owns 36,879 shares of the company’s stock, valued at approximately $490,490.70. The disclosure for this purchase can be found here. Insiders have purchased 30,814 shares of company stock valued at $385,487 over the last three months. 3.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Perspective Therapeutics in the first quarter worth $138,000. Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth $15,511,000. Affinity Asset Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth $6,069,000. Vanguard Group Inc. raised its holdings in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the period. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth $40,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Read More

Analyst Recommendations for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.